Laura Rosenberg
banner
laurarosenberg.bsky.social
Laura Rosenberg
@laurarosenberg.bsky.social
Immunology PhD Candidate in the Vabret Lab at Mount Sinai | Investigating #viralmimicry for #immuno-oncology | Views are my own

www.vabretlab.com
Check out our highlight of an exciting new preprint by Dr. Claudia Rivera from Dr. Yasmine Belkaid's group 👇
November 13, 2025 at 9:29 PM
Reposted by Laura Rosenberg
Very exciting to finally see clinical data where viral mimicry provides survival benefits
This week, that idea reached patients: Viral-mimicry priming + anti-PD-1 in relapsed/refractory NK/T-cell lymphoma delivered 47.6% complete responses, 66.7% ORR, and ~50% 2-year OS, even after prior PD-1 failure (Huang, Cancer Discovery 2025).
November 7, 2025 at 10:11 PM
Reposted by Laura Rosenberg
Proud of our Yu-Chan Chih for receiving the Trainee Innovation Idea Award for his work on cancer vaccination 👏🥇
November 4, 2025 at 3:23 AM
Reposted by Laura Rosenberg
🚀 NY-CURES Launch — Championing State-Wide Investment in Science! 🚀

Our new coalition advocates for sustained public support of New York’s vibrant biomedical research ecosystem — creating cures, economic gains & strengthening communities.

Sign up. Stay informed. Join the movement: www.nycures.org/
September 4, 2025 at 4:32 PM
Reposted by Laura Rosenberg
“Without the funding that went into developing CAR T-cell therapy, I and a lot of other kids would not be here today.” - Emily Whitehead. www.cnn.com/2025/03/07/h...
Cancer survivor warns against threats to health funding | CNN
Emily Whitehead and Tom Whitehead join The Lead
www.cnn.com
March 10, 2025 at 4:27 PM
Reposted by Laura Rosenberg
Today, in #PreprintClubHub1 Oxford’s Alfie Carter will present a #preprint about the way a bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodelling in immune competent preclinical models. ✌️🧠🐁
www.biorxiv.org/content/10.1...
A Bi-Specific T Cell-Engaging Antibody Triggers Protective Immune Memory and Glioma Microenvironment Remodeling in Immune Competent Preclinical Models
Background Bispecific T cell-engagers (BTEs) are engineered antibodies that redirect T cells to target antigen-expressing tumors. BTEs targeting tumor-specific antigens such as interleukin 13 receptor...
www.biorxiv.org
February 19, 2025 at 6:25 AM
Reposted by Laura Rosenberg
Registration is now open for the next ImmunoSchool!

This year’s theme: "10 Years of Discovery in Immunotherapy." We’ve put together a stellar lineup of speakers—don’t miss it!

Free registration @ bit.ly/3WFj0Hc

#ImmunoSchool #Immunotherapy #CancerResearch
February 3, 2025 at 3:18 PM
Reposted by Laura Rosenberg
Very proud of my Ph.D student Ashley who brilliantly defended her thesis last Friday!
January 28, 2025 at 2:30 AM
Reposted by Laura Rosenberg
👀 Read our preprint highlight w/ @natrevimmunol.bsky.social on in vivo enhancement of tumour-specific T cells via peptide–MHC-pseudotyped retroviral gene delivery 👇

www.nature.com/articles/s41...
In vivo enhancement of tumour-specific T cells via peptide–MHC-pseudotyped retroviral gene delivery - Nature Reviews Immunology
A preprint by Xu et al. shows that MHC-pseudotyped retroviruses can reprogramme, activate and expand tumour-specific T cell populations in vivo.
www.nature.com
January 10, 2025 at 9:32 AM
Reposted by Laura Rosenberg
#PreprintClub is now on Bluesky!

Who are we and what are we doing? We are a group of enthusiastic scientists that gather together once a week to discuss fresh preprints in the field of #immunology. 🦠🧬
December 10, 2024 at 1:51 PM